Singapore markets closed

Galapagos NV (GLPG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
30.25-0.60 (-1.94%)
At close: 04:00PM EDT
30.25 0.00 (0.00%)
After hours: 04:01PM EDT

Galapagos NV

Generaal De Wittelaan L11 A3
Mechelen 2800
Belgium
32 1 534 29 00
https://www.glpg.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees1,123

Key executives

NameTitlePayExercisedYear born
Dr. Paulus A. Stoffels M.D., Ph.D.CEO, Chairman, Interim Head of R&D1.35MN/A1962
Mr. Thad HustonExecutive VP, CFO & COON/AN/A1971
Ms. Sofie Van GijselHead of Investor RelationsN/AN/AN/A
Ms. Valeria CnossenExecutive VP & General CounselN/AN/A1974
Marieke VermeerschHead of Corporate CommunicationN/AN/AN/A
Ms. Annelies MissottenExecutive VP & Chief Human Resources OfficerN/AN/A1973
Ms. Ellen Van Der AarHead of DevelopmentN/AN/AN/A
Mr. Philippe Alen M.B.A., Ph.D., Pharm.D.Senior VP & Head of Business DevelopmentN/AN/AN/A
Mr. Dirk De NaeyerHead of Development OperationsN/AN/AN/A
Ms. Alice DietrichHead of Medical AffairsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Corporate governance

Galapagos NV’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 7; Board: 4; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.